The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors
Open accessAbstract
The excess risk of second malignancy after Hodgkin disease is an increasing problem. In light of the long-term data, guidelines for follow-up of survivors of Hodgkin disease need to be redefined. In this study we attempt to analyze the long-term risks and temporal trends, identify patient- and treatment-related risk factors, and determine the prognosis of patients who develop a second malignancy after radiation treatment with or without chemotherapy for Hodgkin disease. Among 1319 patients with clinical stage I-IV Hodgkin disease, 181 second malignancies and 18 third malignancies were observed. With a median follow-up of 12 years, the relative risk (RR) and absolute excess risk of second malignancy were 4.6 and 89.3/10 000 person-years. The RR was significantly higher with combined chemotherapy and radiation therapy (6.1) than with radiation therapy alone (4.0, P = .015). The risk increased with increasing radiation field size (P = .03) in patients who received combined modality therapy, and with time after Hodgkin disease. After 15 and 20 years, there was a 2.3% and 4.0% excess risk of second malignancy per person per year. The 5-year survival after development of a second malignancy was 38.1%, with the worst prognosis seen after acute leukemia and lung cancer. The excess risk of second malignancy after Hodgkin disease continues to be increased after 15 to 20 years, and there does not appear to be a plateau. Our analysis suggests that the risk may be reduced with smaller radiation fields, as are used in current trials of abbreviated chemotherapy and limited-field radiation therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Modelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,065
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,021
Risk of Second Cancers after Treatment for Hodgkin's Disease
Tucker, M. A., Coleman, C. N., Cox, R. S., Varghese, A., & Rosenberg, S. A. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801143180203 · Cited by 718
Medical Treatment of Osteoarthritis
(1965) · The Lancet · doi:10.1016/s0140-6736(65)91263-8 · Cited by 554
Breast Cancer After Treatment of Hodgkin's Disease
Hancock, S. L., Tucker, M. A., & Hoppe, R. T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.1.25 · Cited by 536
Leukemia Following Hodgkin's Disease
Kaldor, J. M., Day, N. E., Clarke, E. A., Van Leeuwen, F. E., Henry-Amar, M., Fiorentino, M. V., Bell, J., Pedersen, D., Band, P., Assouline, D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220102 · Cited by 485
Swerdlow, A. J., Barber, J. A., Hudson, G. V., Cunningham, D., Gupta, R. K., Hancock, B. W., Horwich, A., Lister, T. A., & Linch, D. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.498 · Cited by 476
Cited by
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
Schaapveld, M., Aleman, B. M. P., van Eggermond, A. M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M., Roesink, J., Raemaekers, J. M. M., de Boer, J. P., Zijlstra, J. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505949 · Cited by 637
Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease
Fermé, C., Eghbali, H., Meerwaldt, J. H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., van't Veer, M. B., Walewski, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064601 · Cited by 450
Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma
Travis, L. B., Hill, D., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., Glimelius, B., Andersson, M., Pukkala, E., Lynch, C. F., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji290 · Cited by 425
Radiation and breast cancer: a review of current evidence
Ronckers, C. M., Erdmann, C. A., & Land, C. E. (2004) · Breast Cancer Research · doi:10.1186/bcr970 · Cited by 366
Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma
Hodgson, D. C., Gilbert, E. S., Dores, G. M., Schonfeld, S. J., Lynch, C. F., Storm, H., Hall, P., Langmark, F., Pukkala, E., Andersson, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0936 · Cited by 351
Metadata
- Authors
- Ng, A. K., Bernardo, M. V. P., Weller, E., Backstrand, K., Silver, B., Marcus, K. C., Tarbell, N. J., Stevenson, M. A., Friedberg, J. W., & Mauch, P. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-09-15
- Volume
- 100
- Issue
- 6
- Pages
- 1989-1996
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2082240034
- Cited by
- 433
- References
- 27
- FWCI
- 12.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. https://app.cochat.ai/papers/10.1182/blood-2002-02-0634
- The paper
- Ng, A. K., Bernardo, M. V. P., Weller, E., Backstrand, K., Silver, B., Marcus, K. C., Tarbell, N. J., Stevenson, M. A., Friedberg, J. W., & Mauch, P. M. (2002). Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. https://doi.org/10.1182/blood-2002-02-0634
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.